Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 132,655
  • Shares Outstanding, K 115,352
  • Annual Sales, $ 13,630 K
  • Annual Income, $ -186,260 K
  • EBIT $ -160 M
  • EBITDA $ -150 M
  • 60-Month Beta 2.34
  • Price/Sales 9.39
  • Price/Cash Flow N/A
  • Price/Book 0.55

Options Overview Details

View History
  • Implied Volatility 550.77% (+114.14%)
  • Historical Volatility 72.04%
  • IV Percentile 97%
  • IV Rank 39.90%
  • IV High 1,257.44% on 11/18/25
  • IV Low 81.57% on 06/04/25
  • Expected Move (DTE 5) 0.1615 (14.04%)
  • Put/Call Vol Ratio 0.27
  • Today's Volume 513
  • Volume Avg (30-Day) 255
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 8,554
  • Open Int (30-Day) 7,827
  • Expected Range 0.9885 to 1.3115

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.27
  • Number of Estimates 6
  • High Estimate -0.24
  • Low Estimate -0.30
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +12.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9500 +21.05%
on 11/14/25
1.1650 -1.29%
on 12/12/25
+0.1100 (+10.58%)
since 11/12/25
3-Month
0.9401 +22.33%
on 09/15/25
1.9399 -40.72%
on 10/27/25
+0.1869 (+19.41%)
since 09/12/25
52-Week
0.6611 +73.95%
on 04/04/25
2.0650 -44.31%
on 12/16/24
-0.7750 (-40.26%)
since 12/12/24

Most Recent Stories

More News
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs

FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient treated...

FATE : 1.1500 (+3.60%)
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...

FATE : 1.1500 (+3.60%)
Fate Therapeutics: Q3 Earnings Snapshot

Fate Therapeutics: Q3 Earnings Snapshot

FATE : 1.1500 (+3.60%)
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate...

FATE : 1.1500 (+3.60%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...

FATE : 1.1500 (+3.60%)
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or...

FATE : 1.1500 (+3.60%)
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or...

FATE : 1.1500 (+3.60%)
Fate Therapeutics Appoints New CFO Kamal Adawi

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Fate Therapeutics...

FATE : 1.1500 (+3.60%)
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer

SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (the Company), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem...

FATE : 1.1500 (+3.60%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...

FATE : 1.1500 (+3.60%)

Business Summary

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.' The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the...

See More

Key Turning Points

3rd Resistance Point 1.2550
2nd Resistance Point 1.2100
1st Resistance Point 1.1800
Last Price 1.1500
1st Support Level 1.1050
2nd Support Level 1.0600
3rd Support Level 1.0300

See More

52-Week High 2.0650
Fibonacci 61.8% 1.5287
Fibonacci 50% 1.3630
Fibonacci 38.2% 1.1974
Last Price 1.1500
52-Week Low 0.6611

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar